Related Experiment Video
Updated: Oct 3, 2026

Lipopolysaccharide Infusion as a Porcine Endotoxemic Shock Model
Published on: December 8, 2023
A selective inhibitor for inducible nitric oxide synthase improves hypotension and lactic acidosis in canine
C Mitaka1, Y Hirata, K Yokoyama
1Department of Critical Care Medicine, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. c.mitaka.icu@med.tmd.ac.jp
Objective:
To investigate whether ONO-1714, a putative selective inhibitor for inducible nitric oxide synthase, modulates systemic hemodynamics, arterial blood gases, lactate concentrations, gastric mucosal perfusion, and renal and hepatic functions in endotoxic shock.
Design:
Prospective, randomized, controlled animal study.
Setting:
Laboratory at a university hospital.
Subjects:
Eighteen male beagle dogs (12-19 kg) under pentobarbital anesthesia.
Interventions:
Dogs were mechanically ventilated and monitored with a pulmonary arterial catheter and a gastric tonometer. They were divided in three groups: a) lipopolysaccharide (LPS) plus vehicle group (n = 6), which received LPS (250 ng/kg/min for 2 hrs) and saline 1 hr later; b) LPS plus ONO (0.05) group (n = 6), which received ONO-1714 (0.05 mg/kg) 1 hr after the start of LPS; c) LPS plus ONO (0.1) group (n = 6), which received ONO-1714 (0.1 mg/kg) 1 hr after the start of LPS.
Measurements And Main Results:
Hemodynamics, blood gas parameters, gastric intramural pH, urine output, and serum levels of lactate, transaminases, bilirubin, and creatinine were measured during a 6-hr observation period. LPS induced hypotension, lactic acidosis, gastric mucosal acidosis, and renal and hepatic dysfunction. ONO-1714 reversed the LPS-induced hypotension and lactic acidosis without deteriorating cardiac output, oxygen delivery, or gastric mucosal acidosis.
Conclusions:
These findings suggest that ONO-1714 is a useful agent to reverse hypotension and lactic acidosis in a canine endotoxic shock model.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Nitric Oxide Signaling Pathway
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
